研究者業績

本田 仁

Hitoshi Honda

基本情報

所属
藤田医科大学 感染症科 教授 (臨床教授)
学位
医学博士

J-GLOBAL ID
201501026694891467
researchmap会員ID
B000245187

受賞

 8

論文

 100
  • Paolo Bonanni, Jung Yeon Heo, Hitoshi Honda, Ping-Ing Lee, Aminatou Mouliom, Hoe Nam Leong, Maria Del Pilar Martin Matos, Rachel Dawson
    Infectious diseases and therapy 2025年4月10日  査読有り
    Lower respiratory tract infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) and individuals of all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization and death. National administration schedules for available vaccines against respiratory viruses are not unified, and not all current guidelines are clear and directive, concerning the optimal timing of vaccination. Herein, we formulate an evidence-based position regarding the optimal timing of COVID-19, influenza, and RSV vaccination for older adults and individuals with chronic comorbidities, based on a synthesis of the literature and current guidelines. Vaccination impact and timing were found to be influenced by vaccinee risk factors, including age and comorbidities, and waning vaccine effectiveness and seasonal pathogen burden. Because COVID-19, influenza, and RSV display unique seasonal patterns within and between regions, local epidemiological surveillance of each virus is crucial for determining optimal vaccination timing and guidelines. To maximize the benefits of these respiratory virus vaccines, the timing of peak vaccine effectiveness and period of greatest risk for severe outcomes should be aligned. Thus, COVID-19, influenza, and other recommended vaccines given ahead of the start of the respiratory virus season (or other regionally appropriate time) and co-administered at a single, routine visit represent the optimal approach to protecting at-risk populations. More data will be required to establish the clinical benefit of additional RSV vaccine doses and whether these may be integrated within a seasonal schedule. Coordinated policy decisions that align with strain selection for new and annually reformulated vaccines would enable the timely raising of public health awareness, ultimately leading to enhanced vaccine uptake. Implementation strategies will require engagement of healthcare providers and strong, evidence-based public health recommendations for integrated vaccine schedules.
  • Shogo Hanai, Chiyo Shintani, Yuki Higashimoto, Yuki Uehara, Yohei Doi, Hitoshi Honda
    Infection Control & Hospital Epidemiology 2025年4月3日  
  • Shogo Hanai, Yohei Doi, Hitoshi Honda
    Sexually Transmitted Diseases 2025年2月25日  査読有り最終著者責任著者
  • Yuya Kawamoto, Akane Takamatsu, Kenjiro Matsui, Yohei Doi, Hitoshi Honda
    Infection Control & Hospital Epidemiology 2025年2月14日  査読有り最終著者責任著者
  • Akane Takamatsu, Hitoshi Honda, Toshiki Miwa, Takahiro Tabuchi, Kiyosu Taniguchi, Kenji Shibuya, Yasuharu Tokuda
    Asia-Pacific journal of public health 10105395241305929-10105395241305929 2024年12月17日  査読有り
    Few longitudinal studies have examined the impact of the COVID-19 pandemic on personal behaviors. This study investigated changes in four social behaviors among the Japanese public during and after the COVID-19 pandemic, using four-wave longitudinal data (2020-2023) from the Japan COVID-19 and Society Internet Survey (JACSIS). In total, 8622 respondents continuously participated in the surveys. In JACSIS 2023, the percentage of individuals who always refrained from specific actions decreased compared with 2020: traveling (71.0%-30.9%), non-essential and non-urgent outings (60.6%-24.5%), crowded spaces (62.6%-28.0%), and eating out (49.5%-21.6%). Mixed-effects logistic regression analysis indicated that essential health care workers displayed more cautious behavior than other workers, and respondents were less likely to refrain from these actions in JACSIS 2023 compared with 2020. Understanding behavioral changes is crucial to evaluating the efficacy of COVID-19 prevention measures and improving future pandemic response strategies.

MISC

 106

書籍等出版物

 5

共同研究・競争的資金等の研究課題

 3